Enhanced lymphocyte proliferation in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides

Journal of Inherited Metabolic Disease

Volumn 23, Issue 2, 2000, Pages 113-119

  Barmaki Pour, R ^a   Stockler Ipsiroglu S ^a   Hunneman, D H ^a   Gahr, M ^a   Korenke, G C ^a   Pabst, W ^b   Hanefeld, F ^a   Peters, A ^b  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; LORENZO OIL; MITOGENIC AGENT; OKT 3; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN;

ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; NATURAL KILLER CELL;

ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; CELL DIVISION; CHILD; DIET; DIETARY FATS, UNSATURATED; DRUG COMBINATIONS; ERUCIC ACIDS; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MITOGENS; TRIOLEIN;

EID: 18144447928     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005657530372     Document Type: Article

References (13)

1. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, et al (1993) A two-year trial of oleic and erucic acids (Lorenzo's oil) as treatment for adrenomyeloneuropathy. N Engl J Med 329: 745-752.
2. Chatila TA, Schwartz DH, Miller R, Geha RS (1987) Requirement for mitogen, T cell-accessory cell contact, and interleukin 1 in the induction of resting T cell proliferation. Clin Immunol Immunopathol 44: 235-247.
3. Hunneman DH, Hanefeld F (1987) Diagnose von peroxisomalen Erkrankungen, Erfahrungen einer empfindlichen massenfragmentographischen Bestimmung der sehr langkettigen Fettsäuren und der Phytansäure im Plasma. Monatsschr Kinderheilkd 136: 259.
4. Korenke GC, Hunneman DH, Kohler J, Stöckler S, Landmark K, Hanefeld F (1995) Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effects on clinical, biochemical and neurophysiological parameters. Eur J Pediatr 154: 64-67.
5. Moser HW, Smith KD, Moser AB (1995) X-linked adrenoleukodystrophy. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 2325-2349.
6. Rizzo WB, Leshner RT, Odone A, et al (1989) Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 39: 1415-1422.
7. Seldmayr P, Plecko B, Paschke E, et al (1995) Severely depressed natural killer cell activity of patients with adrenoleukodystrophy under treatment with Lorenzo's oil. J Inherit Metab Dis 18: 101-102.
8. Stöckler S, Molzer B, Plecko B, et al (1993) Giant platelets in erucic acid therapy for adreno-leukodystrophy. Lancet 341: 1414-1415.
9. Stöckler S, Opper C, Greinacher A, et al (1997) Decreased platelet membrane anisotropy in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides. J Inherit Metab Dis 20: 54-58.
10. Unkrig CL, Schröder R, Scharf RE (1994) Lorenzo's oil and lymphocytopenia. N Engl J Med 330: 777.
11. Uziel G, Bertini E, Bardelli P, et al (1991) Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 13: 274-279.
12. Zierz S, Schröder R, Unkrig CL (1993) Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy. Clin Invest 71: 802-805.
13. Zinkham WH, Kickler T, Borel J, Moser HW (1993) Lorenzo's oil and thrombocytopenia in patients with adrenoleukodystrophy. N Engl J Med 328: 1126-1127.